Skip to Content Skip to Search

New GSK, with new ambitions for patients and shareholders

The following information relates to the formation of New GSK and how the company plans to drive growth and returns for shareholders. It is intended for those with a specific interest in this area.

GSK publishes Prospectus and Circular

We have published the Prospectus and Circular for the proposed demerger of our Consumer Healthcare business to form Haleon.

Read the press release

Access the documents

Our CEO Emma Walmsley discusses our strategy for New GSK, the new growth company positioned to create significant value for patients and shareholders from 2022 and for the next decade.

We expect to deliver a step change in performance with major new commitments to sales and profit growth including more than 5% sales CAGR 2021-26, more than 10% adjusted operating profit CAGR 2021-26 expected and an ambition to deliver more than £33 billion sales by 2031. This transformation will be enabled by New GSK’s growth engine, Vaccines and Specialty Medicines, which we expect to grow to around three-quarters of our revenue base by 2026. 

At GSK, we have already delivered unprecedented change over the past four years, improving R&D, becoming a leader in Consumer Health, strengthening our leadership and transforming our commercial execution. Now, we are making our most significant corporate change in more than 20 years, setting out a new ambition for creating value for shareholders and impacting the health of over 2.5 billion people over 10 years. 

New GSK Investor update

Emma Walmsley, CEO, and other members of the GLT hosted a virtual investor update on 23 June 2021. The update provided a clear view of the strategy for New GSK, its outlook for growth and the opportunities we see for shareholder value creation.

Scroll down to watch the event and access the presentations, transcripts, press release and other supplementary information.

Watch the event

Epidemiology data

Clinical trials summary

Our speakers

For media

New GSK to deliver step-change in growth and performance over next ten years driven by high-quality Vaccines and Specialty Medicines portfolio and late-stage pipeline.
Read the press release


Download media call slides

Investor contacts

Media contacts

Global Headquarters (London, UK)

Tim Foley
VP, Global Corporate Media Relations

Madeleine Breckon
Director, Global Corporate Media Relations, Pharmaceuticals

Simon Moore
Director, Global Corporate Media Relations, Vaccines and Global Public Health

Tel: +44 (0)20 8047 5502

USA (Philadelphia)

Kristen Neese
VP, Global Product & Pipeline Communications & US Corporate Communications

Kathleen Quinn
Head, US Corporate Communications

Behind the science

Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.

Go behind the science